Vanguard Group Inc Akebia Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,884,200 shares of AKBA stock, worth $22.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,884,200

Previous 10,070,298 8.08%

Holding current value

$22.9 Million

Previous $13.3 Million 52.3%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$1.26 - $2.13 $1.03 Million - $1.73 Million	813,902 Added 8.08%	10,884,200 $20.2 Million
Q3 2024 Nov 13, 2024	BUY	$0.94 - $1.55 $746,392 - $1.23 Million	794,035 Added 8.56%	10,070,298 $13.3 Million
Q2 2024 Aug 13, 2024	BUY	$0.86 - $1.63 $903,250 - $1.71 Million	1,050,291 Added 12.77%	9,276,263 $9.46 Million
Q1 2024 May 10, 2024	BUY	$1.27 - $2.24 $785,495 - $1.39 Million	618,500 Added 8.13%	8,225,972 $15.1 Million
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $68,924 - $110,278	86,155 Added 1.15%	7,607,472 $9.43 Million
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.84 $252,077 - $533,128	-289,744 Reduced 3.71%	7,521,317 $8.57 Million
Q2 2023 Aug 14, 2023	SELL	$0.51 - $1.43 $2.4 Million - $6.72 Million	-4,699,843 Reduced 37.57%	7,811,061 $7.19 Million
Q1 2023 May 15, 2023	BUY	$0.56 - $1.15 $712,339 - $1.46 Million	1,272,034 Added 11.32%	12,510,904 $7.01 Million
Q4 2022 Feb 10, 2023	SELL	$0.25 - $0.58 $485,998 - $1.13 Million	-1,943,995 Reduced 14.75%	11,238,870 $6.52 Million
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $922,871 - $1.42 Million	-3,076,239 Reduced 18.92%	13,182,865 $4.17 Million
Q2 2022 Aug 12, 2022	BUY	$0.32 - $0.67 $593,957 - $1.24 Million	1,856,116 Added 12.89%	16,259,104 $5.74 Million
Q1 2022 May 13, 2022	BUY	$0.72 - $2.93 $840,469 - $3.42 Million	1,167,319 Added 8.82%	14,402,988 $10.3 Million
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $1.86 Million - $2.75 Million	824,426 Added 6.64%	13,235,669 $29.9 Million
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.88 $600,481 - $991,433	255,524 Added 2.1%	12,411,243 $35.7 Million
Q2 2021 Aug 13, 2021	BUY	$2.83 - $4.2 $34.4 Million - $51.1 Million	12,155,719 New	12,155,719 $46.1 Million

Others Institutions Holding AKBA

# of Institutions

127

Shares Held

56.5M

Call Options Held

291K

Put Options Held

179K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $386M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Akebia Therapeutics, Inc. Transaction History